Cargando…

Preliminary Results of NGS Gene Panel Test Using NSCLC Sputum Cytology and Therapeutic Effect Using Corresponding Molecular-Targeted Drugs

As more molecular-targeted drugs for advanced non-small cell lung cancer are brought to market, batch tests for the identification of gene mutations are needed at initial diagnosis. However, since current gene panel tests require a sufficient amount of tissue sample, there are many instances where p...

Descripción completa

Detalles Bibliográficos
Autores principales: Morikawa, Kei, Kinoshita, Kohei, Kida, Hirotaka, Inoue, Takeo, Mineshita, Masamichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9141607/
https://www.ncbi.nlm.nih.gov/pubmed/35627198
http://dx.doi.org/10.3390/genes13050812
_version_ 1784715385990283264
author Morikawa, Kei
Kinoshita, Kohei
Kida, Hirotaka
Inoue, Takeo
Mineshita, Masamichi
author_facet Morikawa, Kei
Kinoshita, Kohei
Kida, Hirotaka
Inoue, Takeo
Mineshita, Masamichi
author_sort Morikawa, Kei
collection PubMed
description As more molecular-targeted drugs for advanced non-small cell lung cancer are brought to market, batch tests for the identification of gene mutations are needed at initial diagnosis. However, since current gene panel tests require a sufficient amount of tissue sample, there are many instances where panel tests cannot be performed. Therefore, we have developed a highly sensitive next generation sequencing (NGS) panel test to facilitate cytological specimens. Herein, we describe three cases positive for epidermal growth factor receptor (EGFR) exon 19 deletion, MET exon 14 skipping, and KRAS G12A using NGS analysis from sputum. In each case, genetic information was consistent with companion diagnostic analysis obtained from tissue samples collected under bronchoscopy. In cases of EGFR and MET mutations, the corresponding tyrosine kinase inhibitors were highly effective. This is the first report to demonstrate that a novel panel test could detect gene mutations in sputum samples in clinical practice and compare the gene allele ratio with the sample directly collected from the lesion.
format Online
Article
Text
id pubmed-9141607
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-91416072022-05-28 Preliminary Results of NGS Gene Panel Test Using NSCLC Sputum Cytology and Therapeutic Effect Using Corresponding Molecular-Targeted Drugs Morikawa, Kei Kinoshita, Kohei Kida, Hirotaka Inoue, Takeo Mineshita, Masamichi Genes (Basel) Brief Report As more molecular-targeted drugs for advanced non-small cell lung cancer are brought to market, batch tests for the identification of gene mutations are needed at initial diagnosis. However, since current gene panel tests require a sufficient amount of tissue sample, there are many instances where panel tests cannot be performed. Therefore, we have developed a highly sensitive next generation sequencing (NGS) panel test to facilitate cytological specimens. Herein, we describe three cases positive for epidermal growth factor receptor (EGFR) exon 19 deletion, MET exon 14 skipping, and KRAS G12A using NGS analysis from sputum. In each case, genetic information was consistent with companion diagnostic analysis obtained from tissue samples collected under bronchoscopy. In cases of EGFR and MET mutations, the corresponding tyrosine kinase inhibitors were highly effective. This is the first report to demonstrate that a novel panel test could detect gene mutations in sputum samples in clinical practice and compare the gene allele ratio with the sample directly collected from the lesion. MDPI 2022-05-02 /pmc/articles/PMC9141607/ /pubmed/35627198 http://dx.doi.org/10.3390/genes13050812 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Brief Report
Morikawa, Kei
Kinoshita, Kohei
Kida, Hirotaka
Inoue, Takeo
Mineshita, Masamichi
Preliminary Results of NGS Gene Panel Test Using NSCLC Sputum Cytology and Therapeutic Effect Using Corresponding Molecular-Targeted Drugs
title Preliminary Results of NGS Gene Panel Test Using NSCLC Sputum Cytology and Therapeutic Effect Using Corresponding Molecular-Targeted Drugs
title_full Preliminary Results of NGS Gene Panel Test Using NSCLC Sputum Cytology and Therapeutic Effect Using Corresponding Molecular-Targeted Drugs
title_fullStr Preliminary Results of NGS Gene Panel Test Using NSCLC Sputum Cytology and Therapeutic Effect Using Corresponding Molecular-Targeted Drugs
title_full_unstemmed Preliminary Results of NGS Gene Panel Test Using NSCLC Sputum Cytology and Therapeutic Effect Using Corresponding Molecular-Targeted Drugs
title_short Preliminary Results of NGS Gene Panel Test Using NSCLC Sputum Cytology and Therapeutic Effect Using Corresponding Molecular-Targeted Drugs
title_sort preliminary results of ngs gene panel test using nsclc sputum cytology and therapeutic effect using corresponding molecular-targeted drugs
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9141607/
https://www.ncbi.nlm.nih.gov/pubmed/35627198
http://dx.doi.org/10.3390/genes13050812
work_keys_str_mv AT morikawakei preliminaryresultsofngsgenepaneltestusingnsclcsputumcytologyandtherapeuticeffectusingcorrespondingmoleculartargeteddrugs
AT kinoshitakohei preliminaryresultsofngsgenepaneltestusingnsclcsputumcytologyandtherapeuticeffectusingcorrespondingmoleculartargeteddrugs
AT kidahirotaka preliminaryresultsofngsgenepaneltestusingnsclcsputumcytologyandtherapeuticeffectusingcorrespondingmoleculartargeteddrugs
AT inouetakeo preliminaryresultsofngsgenepaneltestusingnsclcsputumcytologyandtherapeuticeffectusingcorrespondingmoleculartargeteddrugs
AT mineshitamasamichi preliminaryresultsofngsgenepaneltestusingnsclcsputumcytologyandtherapeuticeffectusingcorrespondingmoleculartargeteddrugs